Possible association between β-blocker use and a risk of intracranial aneurysm rupture

Pol Arch Intern Med. 2024 Feb 28;134(2):16642. doi: 10.20452/pamw.16642. Epub 2024 Jan 2.

Abstract

Introduction: Aneurysmal subarachnoid hemorrhage is a devastating type of stroke, associated with high mortality and morbidity. One of modifiable risk factors of aneurysm rupture is hypertension, however, it is still not clear whether any particular antihypertensive drugs play a significant role in the prevention of aneurysm rupture.

Objectives: We decided to investigate whether there is any association between acetylsalicylic acid, α-blockers, β‑blockers, angiotensin‑converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, statins, and anticoagulants and a risk of intracranial aneurysm rupture.

Patients and methods: We retrospectively analyzed 334 patients with ruptured and unruptured intracranial aneurysm. Based on logistic regression models, we obtained unadjusted and adjusted odds ratios (ORs) of subarachnoid hemorrhage associated with the use of vasoactive medications and with indices of tortuosity.

Results: We found that β‑blocker intake was significantly related to higher tortuosity of the cerebral arteries. Also, the intake of β‑blockers (OR, 0.41; 95% CI, 0.21-0.77; P = 0.01) and statins (OR, 0.23; 95% CI, 0.05-0.68; P = 0.01) significantly decreased the risk of aneurysm rupture, a result driven by a decreased rupture risk of anterior circulation aneurysms. No such association was found for the posterior part of the cerebral circulation.

Conclusions: Aneurysm located in the anterior cerebral circulation might be less likely to rupture if patients receive β‑blockers or statins.

MeSH terms

  • Adrenergic beta-Antagonists / adverse effects
  • Aneurysm, Ruptured* / complications
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Intracranial Aneurysm* / complications
  • Retrospective Studies
  • Risk Factors
  • Subarachnoid Hemorrhage* / complications

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Adrenergic beta-Antagonists